Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target
Corvus Pharma Analyst Ratings
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target
Mizuho Securities Sticks to Their Hold Rating for Corvus Pharmaceuticals (CRVS)
The Latest Analyst Ratings for Corvus Pharma
Mizuho Reiterates Neutral on Corvus Pharma, Maintains $3.5 Price Target
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)
Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $10
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating
No Data